Director/PDMR Shareholding
Updated : 17:38
GlaxoSmithKline plc (the 'Company' and 'GSK')
Awards under the GSK Deferred Investment Award programme
In accordance with the requirements of the EU Market Abuse Regulation the Company today announces a change in the interests of Persons Discharging Managerial Responsibilities ('PDMR') in notional shares of the Company as a result of awards made under the GlaxoSmithKline Deferred Investment Award programme (the 'Programme') on 3 September 2019. The awards under the Programme will vest on 13 February 2022.
Awards are made over notional Ordinary Shares. Vesting is subject to the individuals not having served GSK notice or having been terminated by GSK for cause. The awards will not accrue dividends, and on vesting, will be paid in cash. Executive Directors are not eligible to receive awards under the Programme.
Both awards relate to the PDMRs' employment prior to their being appointed to GSK's Corporate Executive Team.
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Conrad | |||
b) | Position/status | SVP, Human Resources | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | An award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £17.434 | 10,050 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-09-03 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms S Jackson | |||
b) | Position/status | SVP, Global Communication and CEO Office | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | An award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £17.434 | 10,050 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-09-03 | |||
f) | Place of the transaction
| N/A | |||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.